-
公开(公告)号:US09296813B2
公开(公告)日:2016-03-29
申请号:US14178892
申请日:2014-02-12
申请人: Janine R. Shulok , Feng Cong , Mark C. Fishman , Seth Ettenberg , Michael Bardroff , Mariel Donzeau , Stefanie Urlinger
发明人: Janine R. Shulok , Feng Cong , Mark C. Fishman , Seth Ettenberg , Michael Bardroff , Mariel Donzeau , Stefanie Urlinger
IPC分类号: A61K39/395 , C07K16/22 , C07K16/18 , A61K31/675 , A61K45/06 , A61K39/00
CPC分类号: C07K16/22 , A61K31/675 , A61K39/3955 , A61K45/06 , A61K2039/505 , C07K16/18 , C07K2317/21 , C07K2317/55 , C07K2317/565 , C07K2317/567 , C07K2317/92
摘要: Antibodies and fragments that bind to the protein target Dickkopf (DKK1) are provided, as are methods of use and kits, for treating a target cell, in particular, a cell associated with an osteolytic condition.
摘要翻译: 提供与蛋白质靶标Dickkopf(DKK1)结合的抗体和片段,以及用于治疗靶细胞,特别是与溶骨性病症相关的细胞的使用方法和试剂盒。
-
公开(公告)号:US08388968B2
公开(公告)日:2013-03-05
申请号:US12767509
申请日:2010-04-26
申请人: Catrin Berger , Tanja Herrmann , Chris Lu , Kelly-Ann Sheppard , Estelle Trifilieff , Stefanie Urlinger
发明人: Catrin Berger , Tanja Herrmann , Chris Lu , Kelly-Ann Sheppard , Estelle Trifilieff , Stefanie Urlinger
IPC分类号: A61K39/395 , C07K16/28
CPC分类号: C07K16/2863 , A61K39/3955 , A61K45/06 , A61K2039/505 , C07K16/28 , C07K2317/21 , C07K2317/34 , C07K2317/41 , C07K2317/52 , C07K2317/55 , C07K2317/56 , C07K2317/565 , C07K2317/76 , C07K2317/92
摘要: This disclosure is in the field of anti-Activin receptor IIB (ActRIIB) antibodies. In particular, it relates to the use of said antibodies for treating muscle disorders, such as muscle wasting due to disease or disuse.
-
公开(公告)号:US08106163B2
公开(公告)日:2012-01-31
申请号:US12503175
申请日:2009-07-15
申请人: Christoph Heusser , Julia Neugebauer , Eveline Schaadt , Stefanie Urlinger , Maximilian Woisetschlaeger
发明人: Christoph Heusser , Julia Neugebauer , Eveline Schaadt , Stefanie Urlinger , Maximilian Woisetschlaeger
IPC分类号: C07K16/00
CPC分类号: C07K16/2878 , A61K2039/505 , C07K2317/21 , C07K2317/34 , C07K2317/55 , C07K2317/56 , C07K2317/565 , C07K2317/73 , C07K2317/74 , C07K2317/76
摘要: The present invention relates to antibodies that specifically bind to the BAFF receptor (BAFFR). The invention more specifically relates to specific antibodies that are BAFFR antagonists with in vivo B cell depleting activity and compositions and methods of use for said antibodies to treat pathological disorders that can be treated by killing or depleting B cells, such as systemic lupus erythematosus or rheumatoid arthritis or other autoimmune diseases or lymphomas, leukemias and myelomas.
摘要翻译: 本发明涉及特异性结合BAFF受体(BAFFR)的抗体。 本发明更具体地涉及具有体内B细胞消耗活性的BAFFR拮抗剂的特异性抗体,以及用于治疗可通过杀死或消耗B细胞如系统性红斑狼疮或类风湿病治疗的病理学障碍的所述抗体的组合物和方法 关节炎或其他自身免疫性疾病或淋巴瘤,白血病和骨髓瘤。
-
公开(公告)号:US20140341901A1
公开(公告)日:2014-11-20
申请号:US14163230
申请日:2014-01-24
申请人: Janine R. SHULOK , Feng CONG , Mark C. FISHMAN , Seth ETTENBERG , Michael BARDROFF , Mariel DONZEAU , Stefanie URLINGER
发明人: Janine R. SHULOK , Feng CONG , Mark C. FISHMAN , Seth ETTENBERG , Michael BARDROFF , Mariel DONZEAU , Stefanie URLINGER
IPC分类号: C07K16/22 , A61K45/06 , A61K31/675 , A61K39/395
CPC分类号: C07K16/22 , A61K31/675 , A61K39/3955 , A61K45/06 , A61K2039/505 , C07K16/18 , C07K2317/21 , C07K2317/55 , C07K2317/565 , C07K2317/567 , C07K2317/92
摘要: Antibodies and fragments that bind to the protein target Dickkopf (DKK1) are provided, as are methods of use and kits, for treating a target cell, in particular, a cell associated with an osteolytic condition.
-
公开(公告)号:US08728981B2
公开(公告)日:2014-05-20
申请号:US13884975
申请日:2011-11-18
IPC分类号: C40B30/04
CPC分类号: G01N33/6854 , C07K16/005 , C07K2317/55 , C07K2317/567 , C12N15/1037 , C40B40/08
摘要: The present disclosure enables collections of variable heavy chain and variable light chain pairs comprising, in part, germline protein sequences that are pre-selected for functional properties relevant to developability, wherein the collections may be used to select against any antigen using, for example, phage display.
摘要翻译: 本公开使得可变重链和可变轻链对的收集部分包含预先选择用于与显影性相关的功能性质的种系蛋白序列,其中所述集合可以用于使用例如, 噬菌体展示。
-
公开(公告)号:US08673306B2
公开(公告)日:2014-03-18
申请号:US12160875
申请日:2007-01-12
申请人: Janine Shulok , Feng Cong , Mark Fishman , Seth Ettenberg , Michael Bardroff , Mariel Donzeau , Stefanie Urlinger
发明人: Janine Shulok , Feng Cong , Mark Fishman , Seth Ettenberg , Michael Bardroff , Mariel Donzeau , Stefanie Urlinger
IPC分类号: A61K39/395
CPC分类号: C07K16/22 , A61K31/675 , A61K39/3955 , A61K45/06 , A61K2039/505 , C07K16/18 , C07K2317/21 , C07K2317/55 , C07K2317/565 , C07K2317/567 , C07K2317/92
摘要: Antibodies and fragments that bind to the protein target Dickkopf (DKK1) are provided, as are methods of use and kits, for treating a target cell, in particular, a cell associated with an osteolytic condition.
摘要翻译: 提供与蛋白质靶标Dickkopf(DKK1)结合的抗体和片段,以及用于治疗靶细胞,特别是与溶骨性病症相关的细胞的使用方法和试剂盒。
-
公开(公告)号:US20100272734A1
公开(公告)日:2010-10-28
申请号:US12767509
申请日:2010-04-26
申请人: Catrin Berger , Tanja Herrmann , Chris Lu , Kelly-Ann Sheppard , Estelle TRIFILIEFF , Stefanie Urlinger
发明人: Catrin Berger , Tanja Herrmann , Chris Lu , Kelly-Ann Sheppard , Estelle TRIFILIEFF , Stefanie Urlinger
IPC分类号: A61K39/395 , C07K16/22 , C07H21/04 , C12N15/63 , C12N5/10 , C12P21/00 , A61P21/00 , A61P35/00
CPC分类号: C07K16/2863 , A61K39/3955 , A61K45/06 , A61K2039/505 , C07K16/28 , C07K2317/21 , C07K2317/34 , C07K2317/41 , C07K2317/52 , C07K2317/55 , C07K2317/56 , C07K2317/565 , C07K2317/76 , C07K2317/92
摘要: This disclosure is in the field of anti-Activin receptor IIB (ActRIIB) antibodies. In particular, it relates to the use of said antibodies for treating muscle disorders, such as muscle wasting due to disease or disuse.
摘要翻译: 本公开内容在抗激活素受体IIB(ActRIIB)抗体领域。 特别地,本发明涉及所述抗体用于治疗肌肉疾病的用途,例如由于疾病或不服用而引起的肌肉消瘦。
-
公开(公告)号:US09458240B2
公开(公告)日:2016-10-04
申请号:US13991984
申请日:2011-12-08
申请人: Marta Cosenza , Christoph Heusser , Julia Neugebauer , Eveline Schaadt , Stefanie Urlinger , Maximilian Woisetschlaeger
发明人: Marta Cosenza , Christoph Heusser , Julia Neugebauer , Eveline Schaadt , Stefanie Urlinger , Maximilian Woisetschlaeger
IPC分类号: A61K39/395 , C07K16/18 , C07K16/28 , A61K9/00 , A61K9/08 , A61K9/19 , A61K47/18 , A61K47/26 , C07K14/715 , A61K39/00
CPC分类号: C07K16/2878 , A61K9/0019 , A61K9/08 , A61K9/19 , A61K39/39533 , A61K39/3955 , A61K39/39591 , A61K47/10 , A61K47/183 , A61K47/26 , A61K2039/505 , C07K2317/21 , C07K2317/56 , C07K2317/565 , C07K2317/73
摘要: Anti-BAFFR antibodies are formulated as lyophilisate or liquid formulation. The lyophilisates can be reconstituted to give a solution with a high concentration of the antibody active ingredient for delivery to a patient without high levels of antibody aggregation. The lyophilisate can be reconstituted with an aqueous reconstituent to provide an aqueous composition in which the antibody has a concentration of at least 50 mg/ml. The lyophilisate or aqueous pharmaceutical composition may include one or more of a sugar, a buffering agent, a surfactant, and/or a free amino acid.
摘要翻译: 抗BAFFR抗体配制成冻干液或液体制剂。 可以重构冻干物以产生具有高浓度抗体活性成分的溶液,用于递送至患者,而不需要高水平的抗体聚集。 可以用水重构物重构冻干物,以提供其中抗体具有至少50mg / ml浓度的水性组合物。 冻干物或水性药物组合物可以包括糖,缓冲剂,表面活性剂和/或游离氨基酸中的一种或多种。
-
公开(公告)号:US09382326B2
公开(公告)日:2016-07-05
申请号:US13326569
申请日:2011-12-15
申请人: Christoph Heusser , Julia Neugebauer , Eveline Schaadt , Stefanie Urlinger , Maximilian Woisetschlaeger
发明人: Christoph Heusser , Julia Neugebauer , Eveline Schaadt , Stefanie Urlinger , Maximilian Woisetschlaeger
CPC分类号: C07K16/2878 , A61K2039/505 , C07K2317/21 , C07K2317/34 , C07K2317/55 , C07K2317/56 , C07K2317/565 , C07K2317/73 , C07K2317/74 , C07K2317/76
摘要: The present invention relates to antibodies that specifically bind to the BAFF receptor (BAFFR). The invention more specifically relates to specific antibodies that are BAFFR antagonists with in vivo B cell depleting activity and compositions and methods of use for said antibodies to treat pathological disorders that can be treated by killing or depleting B cells, such as systemic lupus erythematosus or rheumatoid arthritis or other autoimmune diseases or lymphomas, leukemias and myelomas.
摘要翻译: 本发明涉及特异性结合BAFF受体(BAFFR)的抗体。 本发明更具体地涉及具有体内B细胞消耗活性的BAFFR拮抗剂的特异性抗体,以及用于治疗可通过杀死或消耗B细胞如系统性红斑狼疮或类风湿病治疗的病理学障碍的所述抗体的组合物和方法 关节炎或其他自身免疫性疾病或淋巴瘤,白血病和骨髓瘤。
-
公开(公告)号:US09340620B2
公开(公告)日:2016-05-17
申请号:US13326514
申请日:2011-12-15
申请人: Christoph Heusser , Julia Neugebauer , Eveline Schaadt , Stefanie Urlinger , Maximilian Woisetschlaeger
发明人: Christoph Heusser , Julia Neugebauer , Eveline Schaadt , Stefanie Urlinger , Maximilian Woisetschlaeger
IPC分类号: A61K39/395 , C07K16/28 , A61K39/00
CPC分类号: C07K16/2878 , A61K2039/505 , C07K2317/21 , C07K2317/34 , C07K2317/55 , C07K2317/56 , C07K2317/565 , C07K2317/73 , C07K2317/74 , C07K2317/76
摘要: The present invention relates to antibodies that specifically bind to the BAFF receptor (BAFFR). The invention more specifically relates to specific antibodies that are BAFFR antagonists with in vivo B cell depleting activity and compositions and methods of use for said antibodies to treat pathological disorders that can be treated by killing or depleting B cells, such as systemic lupus erythematosus or rheumatoid arthritis or other autoimmune diseases or lymphomas, leukemias and myelomas.
-
-
-
-
-
-
-
-
-